Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx import bill

Executive Summary

Senate is unlikely to vote on drug importation legislation this year, Health Committee Counsel Steve Irizarry says during a Food & Drug Law Institute conference July 28. Sen. Judd Gregg (R-N.H.) postponed the markup of his bill (S 2493) due to the signing of the "BioShield" legislation (1"The Pink Sheet" July 26, 2004, In Brief). There has been speculation that Gregg delayed the markup to assess whether he had sufficient support...

You may also be interested in...

Rx import markup

Senate Health Committee's markup of Sen. Judd Gregg's (R-N.H.) drug importation bill (S 2493) will likely be delayed until September while Gregg assesses whether there is sufficient support for passage. Markup of the bill originally scheduled for July 21 was postponed because it coincided with the White House signing ceremony for the Project BioShield Act of 2004...

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts